Hillhurst Biopharmaceuticals, Inc.
Clinical trials sponsored by Hillhurst Biopharmaceuticals, Inc., explained in plain language.
-
Could carbon monoxide be a medicine? new trial for sickle cell
Disease control Recruiting nowThis early-phase trial tests an oral liquid containing carbon monoxide (HBI-002) in 9 people with sickle cell disease aged 14-55. The goal is to see if it is safe and how the body processes it when taken daily for 14 days. This is not a cure but aims to help manage the disease.
Phase: PHASE1, PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Could carbon monoxide help Parkinson's? new trial launches
Symptom relief Recruiting nowThis study tests an experimental drug called HBI-002, a low-dose carbon monoxide liquid taken by mouth daily for 14 days. It aims to see if the drug is safe and tolerable in 36 adults aged 40-80 with Parkinson's disease. Participants are randomly assigned to receive the drug or a…
Phase: PHASE2 • Sponsor: Hillhurst Biopharmaceuticals, Inc. • Aim: Symptom relief
Last updated May 13, 2026 16:03 UTC